{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06244771",
            "orgStudyIdInfo": {
                "id": "FMC-376-CL101"
            },
            "organization": {
                "fullName": "Frontier Medicines Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors",
            "officialTitle": "An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors",
            "acronym": "PROSPER",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-evaluating-fmc-in-participants-with-kras-mutated-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-19",
            "studyFirstSubmitQcDate": "2024-01-29",
            "studyFirstPostDateStruct": {
                "date": "2024-02-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Frontier Medicines Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumors With KRAS G12C Mutations",
                "Solid Tumor, Adult",
                "Unresectable Solid Tumor",
                "Metastatic Solid Tumor",
                "Non Small Cell Lung Cancer",
                "Colorectal Cancer",
                "KRAS G12C",
                "Pancreatic Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Phase 1A: sequential; Phase 1B and Phase 2: parallel",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 403,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "FMC-376",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Escalation, Dose Expansion, and Cohort Expansion; Administered for 21-day cycle",
                    "interventionNames": [
                        "Drug: FMC-376"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "FMC-376",
                    "description": "Oral Capsule",
                    "armGroupLabels": [
                        "FMC-376"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Limiting Toxicities",
                    "description": "Number of participants with Dose Limiting Toxicities (DLTs)",
                    "timeFrame": "Up to 21 Days"
                },
                {
                    "measure": "Adverse Events (AEs)",
                    "description": "Number of participants with treatment-emergent adverse events (TEAEs)",
                    "timeFrame": "Approximately 24 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum Observed Plasma Concentration (Cmax) of FMC-376",
                    "description": "Cmax",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Time to Reach Maximum Blood Concentration (Tmax) of FMC-376",
                    "description": "Tmax",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Minimum Observed Plasma Concentration (Cmin) of FMC-376",
                    "description": "Cmin",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Elimination Half-life (t1/2) of FMC-376",
                    "description": "t1/2",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Area Under Blood Concentration-Time Curve (AUC) of FMC-376",
                    "description": "AUC",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Volume of Distribution (Vd) of FMC-376",
                    "description": "Vd",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Clearance (CL) of FMC-376 from Blood Plasma",
                    "description": "CL",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "Assess per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Assess per RECIST v1.1",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "Assess per RECIST v1.1",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "description": "Assess per RECIST v1.1",
                    "timeFrame": "Approximately 24 Months"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "timeFrame": "Approximately 24 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors with KRAS G12C mutation\n* Received and progressed or been intolerant to prior standard therapy OR standard therapy is considered inappropriate OR an investigational agent is considered standard of care\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate hematological, renal, and hepatic function\n* Agrees not to participate in another interventional study while receiving study drug\n\nExclusion Criteria:\n\n* Leptomeningeal disease or carcinomatous meningitis\n* Clinically significant toxicity resulting from prior cancer therapies\n* Known or suspected hypersensitivity to FMC-376 or any components of the study drug\n* Condition that would interfere with study drug absorption\n* Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Andrew Krivoshik, MD, PhD",
                    "role": "CONTACT",
                    "phone": "+1 (650) 457-1005",
                    "email": "andrew.krivoshik@frontiermeds.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Andrew Krivoshik, MD, PhD",
                    "affiliation": "Frontier Medicines Corporation",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Florida Cancer Specialists and Research Institute",
                    "status": "RECRUITING",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "407-804-6133",
                            "email": "ajackson@flcancer.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "313-576-9816",
                            "email": "galiciv@karmanos.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator, Research Operations",
                            "role": "CONTACT",
                            "phone": "615-329-7274",
                            "email": "alydia.miller@scri.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics, LLC",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Physician Referral Coordinator",
                            "role": "CONTACT",
                            "phone": "210-593-5265",
                            "email": "isabel.jimenez@startsa.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "START Mountain Region",
                    "status": "RECRUITING",
                    "city": "West Valley City",
                    "state": "Utah",
                    "zip": "84119",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Director, Clinical Operation",
                            "role": "CONTACT",
                            "phone": "801-907-4770",
                            "email": "marie.asay@startthecure.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69161,
                        "lon": -112.00105
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Nurse Navigator",
                            "role": "CONTACT",
                            "phone": "703-636-1473",
                            "email": "carrie.friedman@usoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}